CoJourney Inc., a global innovator in manufacturing and development of cell and gene therapies, has completed a $30 million Series A financing and expansion of its U.S. organization and commercial manufacturing capabilities.

CoJourney has developed high efficiency processes to support end-to-end custom development and manufacturing for genetic medicines, including plasmids, viral vectors, and mRNA. The company has built 130,000 sq.-ft. state-of-the-art cGMP manufacturing facilities that include 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids.

CoJourney’s technology platform and robust and scalable processes are specifically tailored to meet the rigorous demands of commercial-scale manufacturing of genetic medicines. The management team has more than 15 years of operational experience in cell and gene therapy manufacturing globally and leverages this expertise to help expedite production of the highest quality materials for clients.

“I am proud of the highly innovative CDMO platform that CoJourney has built,” said Lijun Wang, CEO, CoJourney Inc. “Our streamlined manufacturing processes and state of the art quality systems and industry-leading cost structure will allow us to deliver the highest purity products to our clients with unprecedented turnaround times and cost structure. We believe this is the new model for cell and gene therapy CDMOs. We are now at a pivotal stage in our company’s journey where we can become true strategic partners for our clients, helping them in their journey to advance innovative genetic medicines from early product development to clinical trial volumes and commercial scale manufacturing. We truly believe that we are embarking on a “co-journey”
with our clients.